This inventor holds 3 USPTO granted patents and 5 published patent applications. Top assignees: Gilead Sciences, Inc., Jounce Therapeutics, Inc.. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: Changyun Hu: Innovator in Antibody Development
Introduction
Changyun Hu is a notable inventor based in Belmont, MA (US), recognized for his contributions to the field of biotechnology. He holds two patents that focus on innovative methods for producing antibodies that target specific human chemokine receptors. His work has significant implications for cancer treatment and therapeutic development.
Latest Patents
Changyun Hu's latest patents include "Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)" and "Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)." These patents detail various embodiments related to antibodies and fusion proteins that bind CCR8. The applications of these antibodies and fusion proteins are particularly relevant in methods aimed at treating cancer.
Career Highlights
Changyun Hu is currently employed at Gilead Sciences, Inc., where he continues to advance his research in antibody development. His work is pivotal in the ongoing efforts to create effective treatments for diseases that involve chemokine receptors.
Collaborations
Changyun has collaborated with esteemed colleagues such as Fabien Dépis and Leonard G Presta, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Changyun Hu's innovative work in the field of antibody development positions him as a key figure in biotechnology. His patents and ongoing research efforts are paving the way for new therapeutic strategies in cancer treatment.